Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Lung Neoplasms Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

4 recruiting trials for Lung Neoplasms. Eligibility criteria explained in plain English.

TrialFinderData lists 4 Lung Neoplasms clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 / Phase 2 is the largest group at 50% (1 studies); the largest phase groups are Phase 1 / Phase 2: 1, Phase 1: 1.

Research is led by Wake Forest University Health Sciences (1), National University Hospital, Singapore (1), Cancer Research UK (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Mobile Low-dose Computed Tomography (LDCT) Screening (other, 1 trial), followed by Liquid Biopsy (SPOT-MAS Assay), Exosome-Based Liquid Biopsy Assay.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
4
Total Trials
4
Recruiting Now
0
Phase 3 Trials
4
Sponsors

Track Lung Neoplasms trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT04577599

Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54

Low-dose CT Screening has been shown in two large trials in the United States (NLST) and Europe (NELSON) to increase overall survival in subjects 55 years of age and older with a...

Sponsor: Wake Forest University Health SciencesEnrolling: 11601 location
RECRUITINGNCT07358715

Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals

This study evaluates the feasibility and cost-effectiveness of using a blood-based liquid biopsy assay as a pre-screening tool before low-dose CT (LDCT) for lung cancer screening....

Sponsor: National University Hospital, SingaporeEnrolling: 1401 location
RECRUITINGPhase 1 / Phase 2NCT05944237

HTL0039732 in Participants With Advanced Solid Tumours

The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other...

Sponsor: Cancer Research UKEnrolling: 1505 locations
RECRUITINGPhase 1NCT06885697

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors...

Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin...

Sponsor: National Cancer Institute (NCI)Enrolling: 1001 location

Frequently Asked Questions

There are currently 4 clinical trials for Lung Neoplasms, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Lung Neoplasms, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Lung Neoplasms, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.